Screening for active small molecules in mitochondrial complex I deficient patient's fibroblasts, reveals AICAR as the most beneficial compound
about
Resveratrol and MyopathyMitochondrial disorders in children: toward development of small-molecule treatment strategiesMitochondrial biogenesis through activation of nuclear signaling proteinsUpregulation of Mitochondrial Content in Cytochrome c Oxidase Deficient FibroblastsPrimary respiratory chain disease causes tissue-specific dysregulation of the global transcriptome and nutrient-sensing signaling networkMitochondria: in sickness and in healthDevelopment of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.Mitochondrial complex IV deficiency, caused by mutated COX6B1, is associated with encephalomyopathy, hydrocephalus and cardiomyopathy.Redox signalling and mitochondrial stress responses; lessons from inborn errors of metabolism.Potential compounds for the treatment of mitochondrial disease.Mitochondrial biogenesis: a therapeutic target for neurodevelopmental disorders and neurodegenerative diseasesThe pleiotropic effects of decanoic acid treatment on mitochondrial function in fibroblasts from patients with complex I deficient Leigh syndrome.Emerging therapies for mitochondrial disorders.Development of pharmacological strategies for mitochondrial disorders.Turn up the power - pharmacological activation of mitochondrial biogenesis in mouse models.Drugs and mitochondrial diseases: 40 queries and answers.Emerging aspects of treatment in mitochondrial disorders.Targeting autophagy and mitophagy for mitochondrial diseases treatment.Defining the action spectrum of potential PGC-1α activators on a mitochondrial and cellular level in vivo.Replacement of the C6ORF66 assembly factor (NDUFAF4) restores complex I activity in patient cells.The Effects of Ascorbate, N-Acetylcysteine, and Resveratrol on Fibroblasts from Patients with Mitochondrial Disorders.Evaluating the therapeutic potential of idebenone and related quinone analogues in Leber hereditary optic neuropathy.Selection and Characterization of Palmitic Acid Responsive Patients with an OXPHOS Complex I Defect.Therapies for mitochondrial diseases and current clinical trials.Combined mineralocorticoid and glucocorticoid deficiency is caused by a novel founder nicotinamide nucleotide transhydrogenase mutation that alters mitochondrial morphology and increases oxidative stress.A novel SUCLA2 mutation in a Portuguese child associated with "mild" methylmalonic aciduria.Postnatal microcephaly and pain insensitivity due to a de novo heterozygous DNM1L mutation causing impaired mitochondrial fission and function
P2860
Q26748160-354C100B-2C2D-4E5B-8E20-DEC0FB25D4B2Q26767327-8F77D81C-81A3-4ABF-A06A-37C06BF7217EQ26991546-1599FC0A-D76B-4FA3-A8DF-F81595349C03Q28392510-CBE61745-2F7C-4DFD-8F80-B87F1A24F18CQ28534824-546C84BA-9FBE-4712-B758-49A898C03CDDQ29614825-C582F4DF-6112-45CB-A1D0-6D6EA130922DQ34538482-40A75BAD-A04B-4A53-9BF0-09D8FBEB504AQ34980882-4FB88900-B20F-4F8D-B9C1-2632D9FDA59AQ35825296-AF2E5090-5749-47FF-818A-AC183BE6B229Q35847813-8617ABDC-06D2-455C-AD45-A600AFFFB862Q36771650-7D250BD1-7CEC-4C4E-BE4C-E6A6913FF32BQ36853449-90A33C43-3111-4112-96DD-B2F97C65C35FQ36967723-C494E48C-29E8-4F0E-BB23-445A1985170CQ37686237-CDC73DD4-36E6-4706-8A6C-B0AFE87851D8Q37686240-176CFDA8-7B89-4C1A-9D06-D5298F981750Q37980195-779C05D3-139C-40F7-8F0A-3A5E7F0492DAQ38472989-6C9149AD-C9A1-447C-8343-41941B6B8F17Q38622293-3971B106-BDB9-44D9-9645-E907DBFCE370Q39295659-CA025B5D-6E26-46F6-890C-ECA4FDF4E0C6Q41967722-8D27F4B5-2DFE-46C8-BCE6-0137C5617578Q42323474-057AD66D-21A5-4901-AF78-326FEF1EC4C9Q42379458-21DF3E43-73A2-49E0-9077-20F5739C5C4FQ43106711-E0F2F583-B256-4429-9AD1-49E2A8A5FDE7Q45872396-F3AB98C3-9A27-409E-A255-5C16446699D5Q46715449-8198753C-2D76-445C-9F05-6F10EEA431EBQ46915438-C5D0D29B-03A7-4332-A0ED-4593D1B1AADBQ52162414-995345BB-0457-47E6-B199-AEEA4B99D6B9
P2860
Screening for active small molecules in mitochondrial complex I deficient patient's fibroblasts, reveals AICAR as the most beneficial compound
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Screening for active small mol ...... s the most beneficial compound
@ast
Screening for active small mol ...... s the most beneficial compound
@en
Screening for active small mol ...... s the most beneficial compound
@nl
type
label
Screening for active small mol ...... s the most beneficial compound
@ast
Screening for active small mol ...... s the most beneficial compound
@en
Screening for active small mol ...... s the most beneficial compound
@nl
prefLabel
Screening for active small mol ...... s the most beneficial compound
@ast
Screening for active small mol ...... s the most beneficial compound
@en
Screening for active small mol ...... s the most beneficial compound
@nl
P2093
P2860
P3181
P1433
P1476
Screening for active small mol ...... s the most beneficial compound
@en
P2093
Anna Golubitzky
Gabriela Link
Phyllis Dan
Sarah Weissman
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0026883
P407
P577
2011-10-26T00:00:00Z